NCT04206813View on ClinicalTrials.gov

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
HPV Infection
Interventions
DRUG

Gardasil 9 2 dose regimen

a 2-dose regimen of Gardasil 9 at 0 and 6 months

DRUG

Gardasil 9 3 dose regimen

standard 3-dose regimen of Gardasil 9 at 0, 2, 6 months

DRUG

Gardasil 9 rescue dose

A rescue dose of Gardasil 9 will be given at 12 months

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Boston Medical Center

OTHER

NCT04206813 - An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | Biotech Hunter | Biotech Hunter